Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

Pfizer, once an underdog in the pharmaceutical world, is poised to disrupt the obesity drug market with a series of Phase 3 trials. Despite initially withdrawing from GLP-1 drug development, Pfizer has since acquired a promising candidate and is now racing to bring a monthly injection option to market. This convenience factor could give Pfizer's product an edge over the once-weekly or daily injections offered by competitors Novo Nordisk and Eli Lilly.

With a robust pipeline of 10 late-stage trials, Pfizer is well-positioned to capture a significant share of the growing GLP-1 market. Investors may have underestimated Pfizer's potential, as evidenced by the company's 5.5% dividend yield, which outpaces its peers. As a long-term dividend investor, now may be an opportune moment to consider adding Pfizer to your portfolio, particularly as the company edges closer to an approved GLP-1 product.